Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons

Péan, Jean-Manuel; Meneï, Philippe; Morel, Olivier; Montero‐Menei, Claudia N.; Benoit, Jean‐Pierre

doi:10.1016/s0142-9612(00)00141-1

Cited by 88 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…112 Each nanoparticle formulation of protein is unique and requires specific adaptation and evaluation. Improved protein stability was achieved by altering preparation processes, 113 by changing polymer/copolymer, 105,114 by changing or mixing solvents, 49,113 by adding protective additives 110,111 such as hydrophilic polymers (PEG 115,116 ), surfactants (poloxamer 188 104,117 ), pro-teins (serum albumin, 118 gelatin 105 ), cyclodextrins 118,119 to the inner aqueous phase. Such formulation optimizations permitted sustained release of active protein over several weeks in vitro.…”

Section: Drug Loadingmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Section: Drug Loadingmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

show abstract

“…Using an unilateral transaction model of the fornix-fimbria, microparticles were implanted by stereotaxic surgery near the septal cholinergic neurons, as the NGF diffusion in the brain tissue from polymeric devices is documented to be limited to 2-3 mm [79]. The percent of cholinergic neurons was increased from 31% and 27% at two and six weeks respectively in non-treated animals, to 66% and 61% in NGF-treated animals in the same period of time, when compared to the contralateral intact side, without any evidence of neural toxicity [89]. Recently, Gu et al [90] implanted microparticles into the basal forebrain of rats with the same animal model of AD.…”

Section: Microparticles For Neurotrophic Factor Deliverymentioning

confidence: 99%

Brain Drug Delivery Systems for Neurodegenerative Disorders

Garbayo

Ansorena

Blanco-Prieto

2012

CPB

View full text Add to dashboard Cite

Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson's, Alzheimer's and Hungtinton's disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.

show abstract

“…In particular, FGF-2 is expressed in osteoblastic cells and has been shown to have important functions in the regulation of bone and cartilage formation. FGF-2 knockout mice show decreased bone mass and bone formation compared to control mice (Montero et al 2000). Initial work on the effect of FGF-2 on adipose-derived stromal cells showed that FGF-2 expression was critical in maintaining clonogenicity and differentiation potential (Zaragosi et al 2006) along with the maintenance of adipose-derived stromal cells proliferation in vitro (Quarto and Longaker, 2006).…”

Section: Fig 1 Bone Morphogenetic Protein Pathwaymentioning

confidence: 99%

“…Our group has formulated PLGA microspheres which deliver therapeutic proteins in a sustained and controlled manner. The use of these growth factor delivery vectors for neuroprotection or for the repair of the nigro-striatal dopaminergic system has been successfully validated in animal models of AD or of PD, respectively (Pean et al, 2000;Jollivet et al, 2004;Menei et al, 2005). In this sense, we developed the PAMs that combine these two approaches and may be easily injected in the desired tissue ( Figure 1).…”

Section: 34mentioning

confidence: 99%

Tissue Engineering for Tissue and Organ Regeneration

Eberli¹

2011

View full text Add to dashboard Cite

Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons

Cited by 88 publications

References 27 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Brain Drug Delivery Systems for Neurodegenerative Disorders

Tissue Engineering for Tissue and Organ Regeneration

Contact Info

Product

Resources

About